SCHEMBL2097353

SCHEMBL2097353

CCOC(=O)C1C2CCC(C2)N1C(=O)OC(C)(C)C

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PREP P48147 4/20 0.61
CHRM1 P11229 7/20 0.52
CHRM2 P08172 1/20 0.52
CHRM3 P20309 1/20 0.52
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
CTSL P07711 1/20 0.38
HSD11B1 P28845 1/20 0.37
NR1H2 P55055 1/20 0.37
GPR119 Q8TDV5 1/20 0.34
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
MAPT P10636 1/20 0.33
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15934580 1.00 PREP (0.61) PREPCHRM1CHRM2CHRM3MEN1
SCHEMBL12294933 1.00 PREP (0.61) PREPCHRM1CHRM2CHRM3MEN1
SCHEMBL17862217 1.00 PREP (0.61) PREPCHRM1CHRM2CHRM3MEN1
SCHEMBL6620964 1.00 PREP (0.61) PREPCHRM1CHRM2CHRM3MEN1
SCHEMBL15934593 1.00 PREP (0.61) PREPCHRM1CHRM2CHRM3MEN1
SCHEMBL6621402 1.00 PREP (0.61) PREPCHRM1CHRM2CHRM3MEN1
SCHEMBL15934699 0.92 PREP (0.55) PREPCHRM1CHRM2CHRM3MEN1
SCHEMBL16071354 0.92 PREP (0.59) PREPCHRM1CHRM2CHRM3MEN1
SCHEMBL29545793 0.92 PREP (0.59) PREPCHRM1CHRM2CHRM3MEN1
SCHEMBL4356385 0.92 PREP (0.59) PREPCHRM1CHRM2CHRM3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110177783-B Hormone receptor modulators for the treatment of metabolic conditions and disorders 阿德利克斯股份有限公司 2023-06-06 CN disclosed
US-20230139597-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2023-05-04 US disclosed
US-20230139597-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2023-05-04 US disclosed
US-20210017177-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2021-01-21 US disclosed
EP-1899294-B1 THERAPEUTIC AGENTS MERCK SHARP & DOHME (GB) 2015-03-18 EP disclosed
US-8163956-B2 Inhibitors of GLYT1 transporters MERCK SHARP & DOHME CORP. (US) 2012-04-24 US disclosed
US-20090286765-A1 Therapeutic Agents MERCK SHARP & DOHME (UK) LIMITED (GB) 2009-11-19 US disclosed
EP-1899294-A1 THERAPEUTIC AGENTS Merck Sharp & Dohme Limited (GB) 2008-03-19 EP disclosed
WO-2006134341-A1 THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286765-A1 Therapeutic Agents GRIA1, GRIN1, GLRA1 PREP 1356/4885CHRM1 409/4885CHRM2 502/4885
US-20230139597-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS NR1H4, FXR1, GLP1R PREP 3622/4885CHRM1 350/4885CHRM2 514/4885
US-20210017177-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS NR1H4, FXR1, GLP1R PREP 3622/4885CHRM1 350/4885CHRM2 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.